Press release
Minimal Residual Disease Market Size in the 7MM was ~700 Million in 2021, estimated DelveInsight
DelveInsight's "Minimal Residual Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Minimal Residual Disease Market with DelveInsight's In-Depth Report @ Minimal Residual Disease Market Size [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Minimal Residual Disease Market Report
* In November 2024:- Pfizer- The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
* According to the statistics published by the American Cancer Society 2022, 34,470 new cases of multiple myeloma in the United States in 2022.
* About 6,660 new cases of acute lymphocytic leukemia (ALL) in 2022.
* As per the statistics published by the Leukemia and Lymphoma Society, in 2021, 90,390 new lymphoma cases were expected to be diagnosed in patients in the United States, of which 8,830 cases would be of Hodgkin lymphoma and 81,560 cases of non-Hodgkin lymphoma.
* The leading Minimal Residual Disease Companies such as Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
* Prominent Minimal Residual Disease Therapies such as ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR Registered PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others
Stay ahead in the Minimal Residual Disease Therapeutics Market with DelveInsight's Strategic Report @ Minimal Residual Disease Market Outlook [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Minimal Residual Disease Epidemiology Segmentation:
* Total Prevalence of Minimal Residual Disease
* Prevalent Cases of Minimal Residual Disease by severity
* Gender-specific Prevalence of Minimal Residual Disease
* Diagnosed Cases of Episodic and Chronic Minimal Residual Disease
Download the report to understand which factors are driving Minimal Residual Disease epidemiology trends @ Minimal Residual Disease Prevalence [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Minimal Residual Disease Market Dynamics
The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.
Minimal Residual Disease Therapies and Companies
* ClonoSEQ: Adaptive Biotechnologies
* PhasED-Seq: Foresight Diagnostics
* Targeted Locus Amplification (TLA) technology: Cergentis B.V.
* MRDx BCR-ABL Test: ICON plc
* TRUPCR Registered PML-RARA: 3B BlacBio Biotech
* Signatera: Natera
* Leukemia Fusion Gene One-Step Detection Kits: EntroGen
* CBFB/MYH11 inv(16): Quest Diagnostics
* Seq-MRD: ImmuQuad
* PhasED-Seq: Foresight Diagnostics
* Targeted Locus Amplification (TLA) technology: Cergentis B.V.
* TRUPCR Registered PML-RARA: 3B BlacBio Biotech
* CBFB/MYH11 inv(16): Quest Diagnostics
* LymphoTrack: Invivoscribe Inc.
* Biocartis: Idylla Technology
Get In-Depth Knowledge on Minimal Residual Disease Market Trends and Forecasts with DelveInsight @ Minimal Residual Disease Treatment Market [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary of Minimal Residual Disease
3. Competitive Intelligence Analysis for Minimal Residual Disease
4. Minimal Residual Disease: Market Overview at a Glance
5. Minimal Residual Disease: Disease Background and Overview
6. Minimal Residual Disease Patient Journey
7. Minimal Residual Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Minimal Residual Disease Unmet Needs
10. Key Endpoints of Minimal Residual Disease Treatment
11. Minimal Residual Disease Marketed Products
12. Minimal Residual Disease Emerging Therapies
13. Minimal Residual Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Minimal Residual Disease Market Outlook
16. Access and Reimbursement Overview of Minimal Residual Disease
17. KOL Views
18. Minimal Residual Disease Market Drivers
19. Minimal Residual Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=minimal-residual-disease-market-size-in-the-7mm-was-700-million-in-2021-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Minimal Residual Disease Market Size in the 7MM was ~700 Million in 2021, estimated DelveInsight here
News-ID: 3742286 • Views: …
More Releases from ABNewswire
The Boulder Group Arranges Sale of Net Leased Florida C-Store
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Cross America Partners C-Store located at 1698 Main Street in Chipley, Florida for $3,464,000.
The 6,998 square-foot building is located along Main Street (15,800 vehicles per day) and benefits from the proximity to Interstate 10, which experiences over 21,500 vehicles per day. Interstate 10 connects Chipley to Tallahassee, FL and Mobile, AL. The property spans…
The Boulder Group Arranges Sale of Net Leased Fast Stop C-Store in New Mexico
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Fast Stop C-Store located at 3 Rio De Arenas Road in Arenas Valley, New Mexico for $2,416,000.
The 2,040-square-foot property sits on a generous 2.4 acre parcel along US Highway 180, a primary thoroughfare that sees approximately 11,800 vehicles per day and serves as a key connector between Silver City and Bayard in southwestern New…
Soulmate Story Review: The Truth Behind Lia Arden's Psychic Soulmate Sketch
Your True Soulmate is Waiting. Are You Ready to Finally Meet Them?
All of us are looking for genuine connections nowadays that dating apps, swiping culture and repetitive dates have become common. People spend years on dating apps going through different profiles and meeting people after people hoping they will find a genuine connection but oftentimes, they fail. This process is lengthy, repetitive, exhausting and also shatters confidence as it makes…
The Memory Wave Review: Boost Memory, Focus & Mental Clarity with Neuroscience A …
12-Minute Brainwave Audio for Sharper Focus & Memory
Your brain changes as you grow. Mental clarity lessens. People get distracted quickly, take more time to concentrate, or find it difficult to stay mentally present throughout the day. These changes can be because of many reasons like stress, bad sleep, and aging. Because of this, interest towards non-medical tools that aim to support cognitive well-being has grown. These are meditation apps, brain-training…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
